CPhI Annual Report–launched ahead of the first CPhI Festival of Pharma (5-16 October, 2020), the world’s largest digital pharma Expo–predicts dramatic growth of new mAb production in China, capacity shortages for cell and gene therapies in the USA, and the widespread global adoption of single-use technologies, but only limited continuous bioprocessing.
Three CPhI experts from BioPlan Associates–Vicky Qing XIA, Leo Cai Yang and Eric Langer–explore the rapidly changing global biologics markets, with special reference to the implications for contract outsourcing and China’s continued emergence as a hub for both bio innovation and contract services.
